Literature DB >> 19240652

INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma.

Christopher W Seder1, Wibisono Hartojo, Lin Lin, Amy L Silvers, Zhuwen Wang, Dafydd G Thomas, Thomas J Giordano, Guoan Chen, Andrew C Chang, Mark B Orringer, David G Beer.   

Abstract

INTRODUCTION: The expression, mechanisms of regulation, and functional impact of activin (INHBA) in esophageal adenocarcinoma (EAC) have not been fully defined.
METHODS: INHBA expression was examined in 46 esophageal samples (nine Barrett's metaplasia (BM); seven BM/low-grade dysplasia; eight low-grade dysplasia; seven high-grade dysplasia; 15 EAC) using oligonucleotide microarrays and real-time reverse transcription-polymerase chain reaction (RT-PCR) and in 90 tissue samples (79 EAC; 8 dysplastic; 3 BM) using immunohistochemistry (IHC). The proliferation of EAC cell lines FLO and OE-33 was examined after treatment with exogenous activin. The proliferation of OE-33 was also examined after treatment with the activin inhibitor follistatin and INHBA-targeting siRNA. OE-33 and FLO cells were treated with 5-aza-2'deoxycytidine (5-AZA) and trichostatin A to investigate the role of epigenetic regulation in INHBA expression.
RESULTS: Primary EACs expressed 5.7-times more INHBA mRNA than BM samples on oligonucleotide microarray. Transcript overexpression in EAC relative to BM was confirmed on real-time RT-PCR. IHC suggested higher INHBA protein expression in EAC (69.6%) than in the dysplastic (37.5%) and BM samples (33.3%). FLO and OE-33 treated with activin demonstrated increased proliferation, and OE-33 cells treated with follistatin and INHBA-targeting siRNA demonstrated reduced proliferation, relative to untreated controls. Treatment of FLO cells with trichostatin A and 5-AZA up-regulated INHBA mRNA and protein production by real time RT-PCR and IHC.
CONCLUSIONS: INHBA is overexpressed in EAC relative to dysplastic and BM tissue. INHBA overexpression may promote cell proliferation and may be affected by promoter demethylation and histone acetylation in EAC cell lines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19240652     DOI: 10.1097/JTO.0b013e31819c791a

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  25 in total

1.  Gene-environment interactions: the potential role of contaminants in somatic growth and the development of the reproductive system of the American alligator.

Authors:  Brandon C Moore; Alison M Roark; Satomi Kohno; Heather J Hamlin; Louis J Guillette
Journal:  Mol Cell Endocrinol       Date:  2011-10-28       Impact factor: 4.102

2.  Activin A-mediated epithelial de-differentiation contributes to injury repair in an in vitro gastrointestinal reflux model.

Authors:  Cedric Roudebush; Alma Catala-Valentin; Thomas Andl; Gregoire F Le Bras; Claudia D Andl
Journal:  Cytokine       Date:  2019-07-29       Impact factor: 3.861

Review 3.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Authors:  Ravindran Caspa Gokulan; Monica T Garcia-Buitrago; Alexander I Zaika
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

Review 4.  Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models.

Authors:  Sally E Henderson; Neil Makhijani; Thomas A Mace
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

5.  Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma.

Authors:  Aparna Kailasam; Sumeet K Mittal; Devendra K Agrawal
Journal:  Clin Transl Sci       Date:  2014-11-12       Impact factor: 4.689

Review 6.  Targeting the myostatin signaling pathway to treat muscle wasting diseases.

Authors:  H Q Han; William E Mitch
Journal:  Curr Opin Support Palliat Care       Date:  2011-12       Impact factor: 2.302

Review 7.  The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy.

Authors:  Michael Grusch; Michaela Petz; Thomas Metzner; Deniz Oztürk; Doris Schneller; Wolfgang Mikulits
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

8.  TGM2: a cell surface marker in esophageal adenocarcinomas.

Authors:  Deborah T Leicht; Tasneem Kausar; Zhuwen Wang; Daysha Ferrer-Torres; Thomas D Wang; Dafydd G Thomas; Jules Lin; Andrew C Chang; Lin Lin; David G Beer
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

9.  Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.

Authors:  M A Hoda; J Münzker; B Ghanim; K Schelch; T Klikovits; V Laszlo; E Sahin; A Bedeir; A Lackner; B Dome; U Setinek; M Filipits; M Eisenbauer; I Kenessey; S Török; T Garay; B Hegedus; A Catania; S Taghavi; W Klepetko; W Berger; M Grusch
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

10.  Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma.

Authors:  Joseph Mazar; Divya Khaitan; Dan DeBlasio; Cuncong Zhong; Subramaniam S Govindarajan; Sharmila Kopanathi; Shaojie Zhang; Animesh Ray; Ranjan J Perera
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.